Review of non-surgical treatment options for Peyronie's Disease

被引:35
作者
Larsen, S. M. [1 ]
Levine, L. A. [1 ]
机构
[1] Rush Univ, Dept Urol, Med Ctr, Chicago, IL 60612 USA
关键词
Peyronie's disease; traction; intralesional injection; oral therapy; non-surgical; GROWTH-FACTOR-BETA; INTRALESIONAL VERAPAMIL INJECTION; SHOCK-WAVE THERAPY; DOUBLE-BLIND; NATURAL-HISTORY; SINGLE-BLIND; PROCARBAZINE NATULAN; PROTEIN EXPRESSION; PARA-AMINOBENZOATE; PENILE CURVATURE;
D O I
10.1038/ijir.2011.45
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Non-surgical treatment of Peyronie's disease (PD) has come a long way since it was first described in 1743. A myriad of treatment options are currently available, including oral, intralesional and external energy therapies. The purpose of this article is to review the contemporary literature on nonsurgical therapies for PD, and where possible, focus on randomized, placebo-controlled trials, as well as review the latest guidelines for the management of PD from the International Committee on Sexual Medicine, which conveyed its findings in July 2009. At this time, it appears that a combination of oral agents and/or intralesional injection with traction therapy may provide a synergy between the chemical effects of the drugs and the mechanical effects of traction. Until a reliable treatment emerges, it does appear that some of the non-surgical treatments discussed can be used to stabilize the scarring process and may result in some reduction of deformity with improved sexual function. International Journal of Impotence Research (2012) 24, 1-10; doi:10.1038/ijir.2011.45; published online 15 September 2011
引用
收藏
页码:1 / 10
页数:10
相关论文
共 85 条
[1]   Intralesional verapamil injections with and without penile traction and oral therapies for management of Peyronie's disease [J].
Abem, Michael R. ;
Levine, Laurence A. .
JOURNAL OF UROLOGY, 2008, 179 (04) :408-408
[2]   IS COLCHICINE EFFECTIVE IN PEYRONIES-DISEASE - A PILOT-STUDY [J].
AKKUS, E ;
CARRIER, S ;
REHMAN, J ;
BREZA, J ;
KADIOGLU, A ;
LUE, TF .
UROLOGY, 1994, 44 (02) :291-295
[3]  
Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6
[4]   PLATELET-DERIVED GROWTH-FACTOR IN FIBROUS MUSCULOSKELETAL DISORDERS - A STUDY OF PATHOLOGICAL TISSUE-SECTIONS AND IN-VITRO PRIMARY-CELL CULTURES [J].
ALMAN, BA ;
NABER, SP ;
TEREK, RM ;
JIRANEK, WA ;
GOLDBERG, MJ ;
WOLFE, HJ .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1995, 13 (01) :67-77
[5]   EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction [J].
Althof, SE ;
Corty, EW ;
Levine, SB ;
Levine, F ;
Burnett, AL ;
McVary, K ;
Stecher, V ;
Seftel, AD .
UROLOGY, 1999, 53 (04) :793-799
[6]  
Armand Jean-Pierre, 2007, Ther Clin Risk Manag, V3, P213
[7]  
BARTSCH G, 1981, EUR J RHEUMATOL INFL, V4, P250
[8]   Intralesional verapamil prevents the progression of Peyronie's disease [J].
Bennett, Nelson E. ;
Guhring, Patricia ;
Mulhall, John P. .
UROLOGY, 2007, 69 (06) :1181-1184
[9]   Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report [J].
Biagiotti, G ;
Cavallini, G .
BJU INTERNATIONAL, 2001, 88 (01) :63-67
[10]  
BODNER H, 1953, Trans West Sect Am Urol Assoc, V20, P32